Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
  • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
  • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/10—Transferases (2.)
  • C12N9/1048—Glycosyltransferases (2.4)
  • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P21/00—Preparation of peptides or proteins
  • C12P21/005—Glycopeptides, glycoproteins
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Y—ENZYMES
  • C12Y204/00—Glycosyltransferases (2.4)
  • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Definitions

• the present invention relates to gonadotrophins for use in the treatment of infertility.
• gonadotrophins for use in the treatment of infertility.
• hCG human chorionic gonadotropin
• the gonadotrophins are a group of heterodimeric glycoprotein hormones which regulate gonadal function in the male and female. They include follicle stimulating hormone (FSH), luteinising hormone (LH) and chorionic gonadotrophin (CG). Human chorionic gonadotrophin (hCG) is naturally secreted by the anterior pituitary gland and functions to support follicular development and ovulation. hCG comprises a 92 amino acid alpha sub-unit, also common to the other glycoprotein hormones LH and FSH, and a 145 amino acid beta sub-unit unique to hCG, which dictates the hormone specificity. Each sub-unit is post translationally modified by the addition of complex carbohydrate residues.
• FSH follicle stimulating hormone
• LH luteinising hormone
• CG chorionic gonadotrophin
• the alpha sub-unit contains 2-N-linked glycosolation sites at amino acids 52 and 78 and the beta sub-unit contains 2-N-linked glycosolation sites at amino acids 13 and 30 and four O-linked glycosylation sites at amino acids 121 , 127, 132 and 138.
• hCG extracted from the urine of pregnant women [Choragon
• hCG isoforms exhibit identical amino acid sequences but differ in the extent to which they are post-translationally modified; particular isoforms are characterised by heterogeneity of the carbohydrate branch structures and differing amounts of sialic acid (a terminal sugar) incorporation, both of which appear to influence the specific isoform bioactivity.
• Glycosylation of natural hCG is highly complex.
• the glycans in naturally derived pituitary hCG can contain a wide range of structures that can include combinations of bi-, tri- and tetra-antennary glycans.
• the glycans can carry further modifications: core fucosylation, bisecting glucosamine, chains extended with acetyl lactosamine, partial or complete sialylation, sialylation with a2,3 and a2,6 linkages, and sulphated galactosamine substituted for galactose.
• core fucosylation bisecting glucosamine
• chains extended with acetyl lactosamine partial or complete sialylation
• sialylation with a2,3 and a2,6 linkages sialylation with a2,3 and a2,6 linkages
• sulphated galactosamine substituted for galactose are differences between the distributions of glycan structures at the
• the glycosylation of recombinant hCG (“rhCG”) products reflects the range of glycosyl-transferases present in the host cell line.
• the existing rhCG product, Ovitrelle is derived from engineered Chinese hamster ovary cells (CHO cells).
• the range of glycan modifications in CHO derived rhCG are more limited than those found on the natural products, derived from urine.
• Examples of the reduced glycan heterogeneity found in CHO derived rhCG include a lack of bisecting glucosamine and a reduced content of core fucosylation and acetyl lactosamine extensions.
• CHO cells are only able to add sialic acid using the a2,3 linkage (Kagawa ei al, 1988, Takeuchi et al, 1988, Svensson ei al., 1990). This is different from naturally produced hCG which contains glycans with a mixture of a2,3 and a2,6-linked sialic acid.
• a recombinant FSH preparation differs in the amounts of FSH with an isoelectric point (pi) of below 4 (considered the acidic isoforms) when compared to pituitary, serum or post-menopausal urine FSH (Ulloa-Aguirre et al. 1995).
• the amount of acidic isoforms in the urinary preparations of FSH was much higher as compared to the recombinant products, Gonal-f (Serono) and Puregon (Organon) (Andersen et al. 2004).
• rFSH Organon
• urine- derived FSH has a higher sialic acid content
• the corresponding plasma clearance rates in the rat are 0.34 and 0.14 ml/min (Ulloa-Aguirre et al. 2003).
• the in vivo potency of the high pi (lower sialic acid content) fraction was decreased and it had a shorter plasma half-life (D'Antonio et al. 1999).
• the known, CHO derived, recombinant hCG product e.g. Ovitrelle
• the known, CHO derived, recombinant hCG product also has a lower amount of hCG with an isoelectric point (pi) of below 4 (considered the acidic isoforms) than urinary hCG, also reflecting a lower sialic acid content of the known rhCG product compared to urinary hCG.
• hCG and rhCG The total sialic acid content of hCG and rhCG is not directly comparable since sialic acids are commonly linked in two ways.
• Pituitary/ serum/ urinary hCG contain both a2,3 and a2,6-linked sialic acid, with a predominance of the former.
• CHO cell derived recombinants only contain a2,3 (Kagawa et al, 1988, Takeuchi et al, 1988, Svensson et a/., 1990).
• recombinant proteins expressed using the CHO system will differ from their natural counterparts in their type of terminal sialic acid linkages.
• rhCG product that more closely replicates or mimics the physiochemical and pharmacokinetic profile of the product produced from human urine. It is desirable to have a rhCG product that has improved pharmacokinetic property or properties compared to the known recombinant product.
• rhCG recombinant hCG
• rhCG or "rechCG”
• the rhCG (or rhCG preparation) according to the invention may have a sialic acid content [expressed in terms of a ratio of moles of sialic acid to moles of protein] of 15 mol/mol or greater, for example of from 15 mol/mol to 25 mol/mol, for example from 17 mol/mol to 24 mol/mol, for example from 17.7 mol/mol to 23 mol/mol, for example from 18 mol/mol to 22 mol/mol, for example from 19 mol/mol to 21 mol/mol, for example from 19 mol/mol to 20 mol/mol.
• the rhCG (or rhCG preparation) according to the invention may have 10% or more of the total sialylation being a2,3-sialylation. For example, 45% to 80% of the total sialylation may be a2,3-sialylation, for example 50% to 70% of the total sialylation may be a2,3-sialylation, for example 55 to 65% of the total sialylation may be a2,3-sialylation.For example 65-85% of the total sialylation may be a2,3-sialylation.
• the rhCG (or rhCG preparation) of the invention may have 50% or less of the total sialylation being a2,6- sialylation.
• 20-55% of the total sialylation may be a2,6- sialylation, for example, 30-50% of the total sialylation may be a2,6- sialylation, for example, 35-45% of the total sialylation may be a2,6- sialylation.
• 15-35% of the total sialylation may be a2,6- sialylation.
• the rhCG (or rhCG preparation) of the invention may have 5% or less of the total sialylation being a2,8-sialylation, for example 0 to 4%, e.g. 0.1-4% of the total sialylation may be a2,8- sialylation.
• the rhCG (or rhCG preparation) of the invention may have no a2,8-sialylation.
• the applicants have developed a human derived recombinant hCG which has a more acidic profile than the CHO derived product, Ovitrelle, and which has a higher sialic acid content.
• the applicants' research indicates that the type of sialic acid linkage, a2,3- or a2,6-, can have a dramatic influence on biological clearance of hCG.
• Human cell lines, as opposed to CHO cell lines, can express recombinant hCG with sialic acids attached by both a2,3 and a2,6 linkages.
• Recombinant hCG with a mixture of both a2,3 and a2,6-linked sialic acid was made by engineering a human cell line to express both rhCG and a2,3 sialyltransferase (Examples 4, 5a and 5b).
• the expressed product is highly acidic and carries a mix of both a2,3- and a2,6-linked sialic acids; the latter provided by the endogenous sialyl transferase activity.
• This has two advantages over rhCG expressed in conventional CHO cells: first the material is more highly sialylated due to the combined activities of the two sialyltransferases; and secondly the material more closely resembles the natural hCG.
• rhCG of the invention may more closely replicate or mimic the physiochemical and pharmacokinetic profile of the natural human urinary product than other recombinant products. In other words, rhCG of the invention may be closer to the "natural" hCG. This may have significant advantages regarding dosing etc. Further, a more "natural” or more "human” product may be more desirable to the patient, who may desire therapy, although in a sense artificial, to be as "natural” as possible. There may be other advantages (e.g. pharmacokinetic advantages) in a recombinant hCG product having carbohydrate (e.g. glycan) structure which is closer to natural (e.g. human urinary) hCG than other recombinant products.
• carbohydrate e.g. glycan
• the invention is thus a recombinant version of hCG which carries a mix of a2,3 and a2,6 sialic acid and therefore more closely resembles natural hCG. It is expected that the use of this compound for controlled ovarian stimulation, in IVF techniques, and ovulation induction will result in a more natural stimulation of the ovary compared to existing recombinant products.
• rhCG recombinant hCG
• rechCG recombinant hCG
• rhCH recombinant hCG
• rhCG preparation including a2, 3 sialylation and a2, 6 sialylation.
• the rhCH or rhCG preparation may optionally further include a2, 8 sialylation.
• recombinant hCG preparation includes a preparation for e.g. pharmaceutical use which includes recombinant hCG.
• the rhCG may be present as a single isoform or as a mixture of isoforms.
• the rhCG (or rhCG preparation) according to the invention may have a sialic acid content [expressed in terms of a ratio of moles of sialic acid to moles of protein] of 15 mol/mol or greater (Example 8), for example of from 15 mol/mol to 25 mol/mol, for example from 17 mol/mol to 24 mol/mol, for example from 17.7 mol/mol to 23 mol/mol, for example from 18 mol/mol to 22 mol/mol, for example from 9 mol/mol to 21 mol/mol, for example from 19 mol/mol to 20 mol/mol.
• the rhCG of the invention may be produced or expressed in a human cell line.
• the rhCG (or rhCG preparation) according to the invention may have 10% or more of the total sialylation being a2,3-sialylation.
• 20, 30, 40, 45, 50, 55, 60, 70, 80 or 90% or more of the total sialylation may be a2,3-sialylation.
• the rhCG (or rhCG preparation) may include a2,3-sialylation in an amount which is from 45% to 80% of the total sialylation, for example 50% to 70% of the total sialylation, for example 55 to 65% of the total sialylation.
• the rhCG (or rhCG preparation) may include a2,3-sialylation in an amount which is from 65 to 85% of the total sialylation, for example from 70 to 80% of the total sialylation, for example from 71 to 79% of the total sialylation.
• the rhCG (or rhCG preparation) of the invention may have 50% or less of the total sialylation being a2,6- sialylation. For example 45, 40, 30, 20, 10, 5% or less of the total sialylation may be a2,6- sialylation.
• the rhCG (or rhCG preparation) may include a2,6-sialylation in an amount which is from 20-55% of the total sialylation, for example, 30-50% of the total sialylation, for example 35- 45% of the total sialylation.
• the rhCG (or rhCG preparation) may include a2,6-sialylation in an amount which is from 15 to 35% of the total sialylation, for example from 20 to 30% of the total sialylation, for example from 21 to 29% of the total sialylation.
• the rhCG (or rhCG preparation) of the invention may have 5% or less of the total sialylation being a2,8- sialylation.
• the rhCG may include a2,8-sialylation in an amount which is from 0 to 4 % of the total sialylation, for example 0.1 to 4% of the total sialylation, for example from 0.5 to 3% of the total sialylation, for example from 0.5 to 2.5% of the total sialylation.
• the rhCG (or rhCG preparation) of the invention may have no a2,8-sialylation.
• sialylation it is meant the amount of sialic residues present on the hCG carbohydrate structures.
• a2,3-sialylation means sialylation at the 2,3 position (as is well known in the art) and a2,6 sialylation at the 2,6 position (also well known in the art).
• % of the total sialylation may be a 2,3 sialylation” refers to the % of the total number of sialic acid residues present in the hCG which are sialylated in the 2,3 position.
• % of the total sialylation being a2,6-sialylation refers to the % of the total number of sialic acid residues present in the hCG which are sialylated in the 2,6 position.
• the rhCG (or rhCG preparation) according to the invention may have a sialic acid content (amount of sialylation per hCG molecule) of (based on the mass of protein, rather than the mass of protein plus carbohydrate) of 6% or greater (e.g. between 6% and 15%, e.g. between 7% and 13%, e.g. between 8% and 12%, e.g. between 1 1 % and 15%, e.g. between 12% and 14%) by mass.
• sialic acid content amount of sialylation per hCG molecule
• 6% or greater e.g. between 6% and 15%, e.g. between 7% and 13%, e.g. between 8% and 12%, e.g. between 1 1 % and 15%, e.g. between 12% and 14%) by mass.
• Recombinant hCG expressed in Chinese hamster ovary (CHO) cells includes exclusively a 2, 3 sialylation.
• the rhCG of the invention may be produced or expressed in a human cell line. This may simplify (and render more efficient) the production method because manipulation and control of e.g. the cell growth medium to retain sialylation may be less critical than with known processes. The method may also be more efficient because there is less basic rhCG produced than in production of known rhCG products; more acidic rhCG is produced and separation/removal of basic hCG is less problematic.
• the rhCG may be produced or expressed in a Per.C6 cell line, a Per.C6 derived cell line or a modified Per.C6 cell line.
• the cell line may be modified using a2,3-sialyltransferase.
• the rhCG may include a2,6-linked sialic acids (a2,6 sialylation) provided by endogenous sialyl transferase activity [of the cell line].
• the cell line may be modified using ct2,6-sialyltransferase.
• the rhCG may be produced using a2,3- sialyltransferase.
• the rhCG may include a2,6-linked sialic acids (a2,6 sialylation) provided by endogenous sialyl transferase activity.
• the rhCG may be produced using a2,3- and/or a2,6-sialyltransferase.
• a method of production of rhCG and/or an rhCG preparation as described herein comprising the step of producing or expressing the rhCG in a human cell line, for example a Per.C6 cell line, a Per.C6 derived cell line or a modified Per.C6 cell line, for example a cell line which has been modified using a2,3- sialyltransferase.
• a human cell line for example a Per.C6 cell line, a Per.C6 derived cell line or a modified Per.C6 cell line, for example a cell line which has been modified using a2,3- sialyltransferase.
• the rhCG structure contains glycan moieties. Branching can occur with the result that the glycan may have 1 , 2, 3, 4 or more terminal sugar residues or "antennae", as is well known in the art.
• the rhCG of the invention may have glycans with sialylation presence on mono-antennary and/or di-antennary and/or tri-antennary and/or tetra-antennary structures.
• the rhCG may include mono-sialylated, di- sialylated, tri- sialylated and tetra- sialylated glycan structures, for example with relative amounts as follows: 0.1-4% mono-sialylated; 35 - 45% di— sialylated; 0.5 - 8% tri— sialylated and 0 - 1 % tetra-sialylated (e.g. as shown by WAX analysis of charged glycans, as set out in Example 8 D).
• the recombinant hCG of the invention includes mono (1 S), di(2S), tri(3S) and tetra(4S) sialylated structures.
• the relative amounts of sialylated structures are in the following ratios (1 S:2S:4S:4S): 0.2-1 %: 35-40%: 2.5- 7%: 0.5-1 % (e.g. as shown by WAX analysis of charged glycans, as set out in Example 8 D).
• rhCG produced (e.g. expressed) in a human cell line.
• the rhCG may include a2,3- and a2,6-sialylation.
• the rhCG may be produced or expressed in a Per.C6 cell line, a Per.C6 derived cell line or a modified Per.C6 cell line.
• the cell line may be modified using a2,3- sialyltransferase.
• the rhCG may include a2,6-linked sialic acids (a2,6 sialylation) provided by endogenous sialyl transferase activity [of the cell line].
• the cell line may be modified using a2,6- sialyltransferase.
• the rhCG (or rhCG preparation) according to the invention may have a sialic acid content [expressed in terms of a ratio of moles of sialic acid to moles of protein] of 15 mol/mol or greater, for example of from 15 mol/mol to 25 mol/mol, for example of from 17 mol/mol to 24 mol/mol, for example from 17.7 mol/mol to 23 mol/mol, for example from 18 mol/mol to 22 mol/mol, for example from 19 mol/mol to 21 mol/mol, for example from 9 mol/mol to 20 mol/mol.
• a sialic acid content expressed in terms of a ratio of moles of sialic acid to moles of protein
• the rhCG (or rhCG preparation) may have 10% or more of the total sialylation being a2,3- sialylation, for example 45% to 80% of the total sialylation may be a2,3- sialylation, for example 50% to 70% of the total sialylation may be a2,3- sialylation, for example 55 to 65% of the total sialylation may be a2,3- sialylation. For example 65-85% of the total sialylation may be a2,3- sialylation.
• the rhCG (or rhCG preparation) of the invention may have 50% or less of the total sialylation being a2,6-sialylation.
• 20- 55% of the total sialylation may be a2,6- sialylation, for example, 30-50% of the total sialylation may be a2,6- sialylation, for example, 35-45% of the total sialylation may be a2,6- sialylation.
• 15-35% of the total sialylation may be a2,6- sialylation.
• the rhCG (or rhCG preparation) of the invention may have 5% or less of the total sialylation being a2,8- sialylation, for example 0 to 4%, e.g. 0.5-4% of the total sialylation may be 0:2,8- sialylation.
• the rhCG (or rhCG preparation) of the invention may have no a2,8-sialylation.
• a pharmaceutical composition comprising rhCG including a2,3- sialylation and a2,6-sialylation (e.g. as set out above).
• the pharmaceutical composition may further comprise FSH and/or LH.
• FSH can be obtained by any means known in the art.
• FSH as used herein includes human-derived and recombinant FSH.
• Human-derived FSH can be purified from any appropriate source (e.g. urine) by any method known in the art.
• the FSH may be recombinant FSH - for example expressed in a human cell line. Methods of expressing and purifying recombinant FSH are well known in the art.
• LH can be obtained by any means known in the art.
• LH as used herein, includes human-derived and recombinant LH.
• Human-derived LH can be purified from any appropriate source (e.g. urine) by any method known in the art. Methods of expressing and purifying recombinant LH are known in the art.
• the pharmaceutical composition may be for the treatment of infertility, e.g. for use in e.g. assisted reproductive technologies (ART), ovulation induction or intrauterine insemination (IUI).
• the pharmaceutical composition may be used, for example, in medical indications where known hCG preparations are used.
• the present invention also provides the use of rhCG and/or an rhCG preparation described herein (according to aspects of the invention) for, or in the manufacture of a medicament for, the treatment of infertility.
• the pharmaceutical compositions of the present invention can be formulated into well-known compositions for any route of drug administration, e.g. oral, rectal, parenteral, transdermal (e.g.
• a typical composition comprises a pharmaceutically acceptable carrier, such as aqueous solution, non toxic excipients, including salts and preservatives, buffers and the like, as described in Remington's Pharmaceutical Sciences fifteenth edition (Matt Publishing Company, 1975), at pages 1405 to 1412 and 1461 - 87, and the national formulary XIV fourteenth edition (American Pharmaceutical Association, 1975), among others.
• a pharmaceutically acceptable carrier such as aqueous solution, non toxic excipients, including salts and preservatives, buffers and the like, as described in Remington's Pharmaceutical Sciences fifteenth edition (Matt Publishing Company, 1975), at pages 1405 to 1412 and 1461 - 87, and the national formulary XIV fourteenth edition (American Pharmaceutical Association, 1975), among others.
• aqueous and non-aqueous pharmaceutical carriers, diluents, solvents or vehicles examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil), and injectible organic esters such as ethyl oleate.
• the compositions of the present invention also can contain additives such as but not limited to preservatives, wetting agents, emulsifying agents, and dispersing agents.
• Antibacterial and antifungal agents can be included to prevent growth of microbes and includes, for example, paraben, chlorobutanol, phenol, sorbic acid, and the like.
• isotonic agents such as sugars, sodium chloride, and the like.
• hCG hCG
• other active ingredients if present
• hCG hCG
• a liquid suspension of crystalline or amorphous material with poor water solubility The rate of absorption of hCG then depends upon its rate of dissolution which, in turn, can depend upon crystal size and crystalline form.
• delayed absorption of a parenterally administered hCG combination form is accomplished by dissolving or suspending the hCG combination in an oil vehicle.
• Injectable depot forms can be made by forming microencapsule matrices of the hCG (and other agents, if present) in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of hCG to polymer and the nature of the particular polymer employed, the rate of hCG release can be controlled. Examples of other biodegradable polymers include polyvinylpyrrolidone, poly(orthoesters), poly(anhydrides) etc. Depot injectable formulations are also prepared by entrapping the hCG in liposomes or microemulsions which are compatible with body tissues.
• Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
• Injectable formulations can be supplied in any suitable container, e.g. vial, pre-filled syringe, injection cartridges, and the like.
• Injectable formulations can be supplied as a product having pharmaceutical compositions containing hCG (optionally with FSH, LH etc.) If there is more than one active ingredient (i.e. hCG and e.g. FSH or LH) these may be suitable for administration separately or together. If administered separately, administration can be sequential.
• the product can be supplied in any appropriate package.
• a product can contain a number of pre-filled syringes containing either hCG, FSH, or a combination of both FSH and hCG, the syringes packaged in a blister package or other means to maintain sterility.
• a product can optionally contain instructions for using the hCG and FSH formulations.
• compositions of the invention are supplied as compositions for parenteral administration.
• General methods for the preparation of the parenteral formulations are known in the art and are described in REMINGTON; THE SCIENCE AND PRACTICE OF PHARMACY, supra, at pages 780-820.
• the parenteral compositions can be supplied in liquid formulation or as a solid which will be mixed with a sterile injectable medium just prior to administration.
• the parenteral compositions are supplied in dosage unit form for ease of administration and uniformity of dosage.
• Figure 1 shows a plasmid map of the phCGalpha/beta expression vector
• Figure 2 shows the a2,3-sialyltransferase (ST3GAL4) expression vector
• Figure 3 shows the a2,6-sialyltransferase (ST6GAL1) expression vector
• Figure 4 shows the detection of rhCG Isoforms in human cell line derived recombinant hCG preparations according to the invention (track 3, 4) by IEF stained with Coomassie Blue, compared with preparations of the prior art (track 1 , 2);
• FIG. 5 shows metabolic clearance rates (MCRs) of a2,3-sialytransferase engineered Per.C6 hCG samples.
• Figure 6 shows long term MCRs of a2,3 sialyltransferase engineered Per.C6 rhCG samples
• the coding region of the gene for the hCG alpha polypeptide was used according to Fiddes and Goodman (1979). The sequence is banked as AH007338 and at the time of construction there were no other variants of this protein sequence. The sequence is referred to herein as SEQ ID 1.
• the coding region of the gene for hCG beta polypeptide was used according to Fiddes and Goodman (1980).
• the sequence is banked as NP_000728 and is consistent with the protein sequences of CGbeta3, CGbeta5 and CGbeta7.
• the sequence is referred herein as SEQ ID 2
• Sialyltransferase a2,3-Sialyltransferase - The coding region of the gene for beta-galactoside alpha-2,3-sialyltransferase 4 (a2,3-sialyltransferase, ST3GAL4) was used according to Kitagawa and Paulson (1994). The sequence is banked as L23767 and referred herein as SEQ ID 3.
• ct2,6-Sialyltransferase The coding region of the gene for beta- galactosamide alpha-2,6-sialyltransferase 1 (a2,6-sialyltransferase, ST6GAL1) was used according to Grundmann et al. (1990). The sequence is banked as NM_003032 and referred herein as SEQ ID 4.
• hCG alpha polypeptide AH007338, SEQ ID 1
• hCG beta polypeptide NP_000728, SEQ ID 2
• the resulting amplified hCG beta DNA was digested with the restriction enzymes Asc ⁇ and Hpal and inserted into the Asc ⁇ and Hpa ⁇ sites on the CMV driven mammalian expression vector carrying a neomycin selection marker.
• the hCG alpha DNA was digested with BamHI and Nhe ⁇ and inserted into the sites BamH ⁇ and Nhe ⁇ on the expression vector already containing the hCG beta polypeptide DNA.
• the vector DNA was used to transform the DH5a strain of E.coli. Colonies were picked for amplification and, of the number which included the vector containing both hCG alpha and beta, twenty were selected for sequencing. All colonies selected for sequencing contained the correct sequences according to SEQ ID 1 and SEQ ID 2. Plasmid phCG A+B was selected for transfection ( Figure 1 ).
• beta-galactoside alpha-2,3-sialyltransferase 4 (ST3, L23767, SEQ ID 3) was amplified by PCR using the primer combination 2,3STfw and 2,3STrev.
• the resulting amplified ST3 DNA was digested with the restriction enzymes Bam ⁇ and AflW and inserted into the BamHl and AflU sites on the CMV driven mammalian expression vector carrying a hygromycin resistance marker.
• the vector was amplified as previously described and sequenced.
• Clone pST3#1 ( Figure 2) contained the correct sequence according to SEQ ID 3 and was selected for transfection.
• the coding sequence of beta-galactosamide alpha-2,6-sialyltransferase 1 (ST6, NM_003032, SEQ ID 4) was amplified by PCR using the primer combination 2,6STfw and 2,6STrev.
• Example 4 Stable expression of phCG A+B in PER.C6 cells. Transfection isolation and screening of clones.
• Per.C6 clones producing hCG were generated by expressing both polypeptide chains of hCG from a single plasmid (see Example 1).
• a liposome based transfection agent was used with the phCG A+B construct. Stable clones were selected in Per.C6 selection media supplemented with 10% FCS and containing G418. Three weeks after transfection G418 resistant clones grew out. A total of 389 clones were selected for isolation. The isolated clones were cultured in selection medium until 70-80% confluent. Supernatants were assayed for hCG protein content using an hCG selective ELISA and pharmacological activity at the hCG receptor in cloned cell line, using a cAMP accumulation assay. Clones (1 8) expressing functional protein were progressed for culture expansion to 24 well, 6 well and T80 flasks.
• Per.C6 clones producing highly sialylated hCG were generated by expressing a2,3 sialyltransferase from separate plasmids (see Example 2) in Per.C6 cells already expressing both polypeptide chains of hCG (see Example 4). Clones produced from PER.C6® cells as set out in Example 4 were selected for their characteristics including productivity, good growth profile, production of functional protein, and produced hCG which included some sialylation.
• Stable clones were generated as previously described in Example 4. Clones from the a2,3-sialyltransferase program were isolated, expanded and assayed. The final clone number for the a2,3- study was five. The a2,3-sialyltransferase clones were adapted to serum free media and suspension conditions.
• clones were assayed using a hCG selective ELISA, functional response in an hCG receptor cell line, IEF (Example 6). They were also assessed for metabolic clearance rate (Example 9) and USP hCG Bioassay (Example 10). Results were compared to a commercially available recombinant hCG (Ovitrelle, Serono) and the parental hCG Per.C6 cell lines. Representative samples are shown in the Examples and Figures.
• the alpha beta heterodimer produced above had a low level of sialylation resulting in a very basic IEF profile.
• expression of hCG together with a2,3-sialyltransferase in Per.C6 cells results in increased levels of sialylated hCG compared to cells expressing hCG only.
• a double transfection of the hCG alpha and beta subunit genes together with the a2,3 sialyltransferase enzyme gene into Per.C6 cells in suspension cell culture format was performed.
• hCG vector dual alpha/beta, Example 1
• a2,3-sialyltransferase Example 2
• Clones produced from PER.C6® cells were selected for their characteristics including productivity, good growth profile, production of functional protein, and produced hCG which included some sialylation. Clones were isolated, expanded and assayed. As before clones were assayed using a hCG selective ELISA, functional response in an hCG receptor cell line, IEF (Example 6). They were also assessed for metabolic clearance rate (Example 9) and USP hCG Bioassay (Example 10).
• Results were compared to a commercially available recombinant hCG (Ovitrelle, Serono) and the parental hCG Per.C6 cell lines. Representative samples are shown in the Examples and Figures (see Examples 6, 9, 10, Figs 4 and 5).
• the recombinant hCG produced by the clones (that is, recombinant hCG according to the invention) has significantly improved sialylation (i.e. on average more hCG isoforms with high numbers of sialic acids), compared to hCG expressed without a2,3- sialyltransferase and Ovitrelle (see Examples 6 and 8, Fig 4).
• Example 6 Analysis of the isoelectric point pi of Per.C6 produced hCG isoforms by isoelectric focussing.
• Electrophoresis is defined as the transport of charged molecules through a solvent by an electrical field.
• the mobility of a biological molecule through an electric field will depend on the field strength, net charge on the molecule, size and shape of the molecule, ionic strength and properties of the medium through which the molecules migrate.
• Isoelectric focusing is an electrophoretic technique for the separation of proteins based on their pi.
• the pi is the pH at which a protein has no net charge and will not migrate in an electric field.
• the sialic acid content of the hCG isoforms subtly alters the pi point for each isoform, which can be exploited using this technique to visualise the Per.C6 hCG isoforms from each clone.
• the isoelectric points of the Per.C6 produced hCG isoforms in cell culture supernatants were analyzed using isoelectric focussing.
• Cell culture media from Per.C6 hCG clones were produced as described in Example 4, 5a and 5b.
• Per.C6 hCG samples were separated on Novex® IEF Gels containing 5% polyacrylamide under native conditions on a pH 3.0 -7.0 gradient in an ampholyte solution pH 3.0 - 7.0. Proteins were visualised using Coomassie Blue staining, using methods well known in the art.
• Figure 4 shows the detection of rhCG Isoforms by IEF stained with Coomassie Blue in compositions according to the invention (Track 3, 10 pg, and Track 4, 15pg) and the CHO derived composition of the prior art, Ovitrelle (Track 1 , Ovitrelle, 10 pg, and Track 2, Ovitrelle, 15pg).
• the bands represent isoforms of hCG containing different numbers of sialic acid molecules.
• clones producing hCG isoforms with a higher number of sialic acid molecules were identified.
• Figure 4 indicates that human cell line derived recombinant hCGs engineered with a2,3- sialyltransferase (compositions according to the invention) have a more acidic profile than Ovitrelle.
• Glycoconjugates were analyzed using a lectin based glycan differentiation method. With this method glycoproteins and glycoconjuagtes bound to nitrocellulose can be characterized. Lectins selectively recognize a particular moiety, for example a2,3 linked sialic acid. The lectins applied are conjugated with the steroid hapten digoxigenin which enables immunological detection of the bound lectins.
• Sialic acid was analyzed using the DIG Glycan Differentiation Kit (Cat. No. 11 210 238 001 , Roche) according to the manufacturers instructions. Positive reactions with Sambucus nigra agglutinin (SNA) indicated terminally linked (2-6) sialic acid. Positive reactions with Maackia amurensis agglutinin II (MAA): indicated terminally linked (a2-3) sialic acid
• SNA Sambucus nigra agglutinin
• MAA Maackia amurensis agglutinin II
• the parental clone contained low levels of both a2,3- and 0:2,6- sialic acid.
• the clones engineered with a2,3-sialyltransferase contained high levels of a2,3- sialic acid linkages and low levels of a2,6- sialic acid linkages.
• the standard control Ovitrelle only contains a2,3- sialic acid linkages. This is consistent with what is known about recombinant proteins produced in Chinese Hamster ovary (CHO) cells (Kagawa er a/, 1988, Takeuchi et al, 1988, Svensson et al., 1990).
• Sialic acid is a protein-bound carbohydrate considered to be a monosaccharide and occurs in combination with other mono- saccharides like galactose, mannose, glucosamine, galactosamine and fucose.
• the total sialic acid on purified rhCG according to the invention was measured using a method based on the method of Stanton et. al. (J. Biochem. Biophys. Methods. 30 (1995), 37 - 48).
• the total sialic acid content of Per.C6 recombinant hCG modified with a2,3- sialyltransferase (e.g. Example 5a, Example 5b) was measured and found to be greater than 15 mol/mol, [expressed in terms of a ratio of moles of sialic acid to moles of protein], for example greater than 18 mol/mol, for example 19.1 mol/mol. This can be compared to Ovitrelle which has total sialic acid content of 17.6 mol/mol.
• the total sialic acid content of Per.C6 recombinant hCG modified with a2,3- sialyltransferase 080019-19 was measured and found to be 20 mol/mol, [expressed in terms of a ratio of moles of sialic acid to moles of protein]. Again, this may be favourably compared with Ovitrelle which has total sialic acid content of 17.6 mol/mol.
• This Example (080019-19) was tested to quantify the relative amounts of a2,3 and a2,6 sialic acid (Example 8C).
• Example 8C Quantification of relative amounts of a2,3 and a2,6 sialic acid
• the relative percentages were found to be in the ranges 55% - 65% (e.g. 59%) for 0:2,3 sialylation; and 35 to 45% (e.g. 41%) for a2,6 sialylation.
• N-glycans for NP-HPLC and WAX-HPLC analysis were labelled with the fluorophore 2AB as detailed in Royle et al.
• the relative amounts of sialylated structures were in the following ratios (1S:2S:4S:4S): 0.1-4%: 35-45%: 0.5-8%: 0-1 %.
• MCR metabolic clearance rate
• a hCG Bioassay was carried out, to assay the hCG specific activity.
• the activity was measured according to USP (USP Monographs: Chorionic Gonadotropin, USPC Official 8/1/09-1 1/30/09), using Ovitrelle as a standard.
• Ovitrelle has a biological activity of 26,000 lU/mg (Curr Med Res Opin. 2005 Dec; 21(12): 1969 - 76).
• the acceptance limit was >21 ,000 IU hCG/mg.
• the biological activity for a sample of human cell line derived hCG recombinant hCG engineered with a2,3- sialyltransferase was 27,477 IU hCG/mg.
• Recombinant hCG from an a2,3- clone was prepared using a using a modification of the method described by Lowry et a/. (1976).
• the cell lines were adapted to a serum- free medium, i.e., Excell 525 (JRH Biosciences).
• the cells were first cultured to form a 70%-90% confluent monolayer in a T80 culture flask. On passage the cells were re-suspended in the serum free medium, Excell 525 + 4 mM L-Glutamine, to a cell density of 0.3x 0 6 cells/ml.
• a 25 ml cell suspension was put in a 250 ml shaker flask and shaken at 100 rpm at 37°C at 5% C0 2 .
• the cells were sub-cultured to a cell density of 0.2 or 0.3x10 6 cells/ml and further cultured in shaker flasks at 37°C, 5% C0 2 and 100 rpm.
• VPRO serum-free production medium
• VPRO JRH Biosciences
• the cells were first cultured to > IxlO 6 cells/ml in Excell 525, then spun down for 5 min at 1000 rpm and subsequently suspended in VPRO medium + 6 mM L-glutamine to a density of 1x10 6 cells/ml.
• the cells were then cultured in a shaker flask for 7-10 days at 37°C, 5% C02 and 100 rpm. During this period, the cells grew to a density of > 10 7 cells/ml.
• the culture medium was harvested after the cell viability started to decline.
• the cells were spun down for 5 min at 1000 rpm and the supernatant was used for the quantification and purification of hCG.
• the concentration of hCG was determined using ELISA (DRG EIA 1288).
• purification of hCG was carried out using a modification of the method described by Lowry et al. (1976). This was achieved by chromatography on DEAE cellulose, gel filtration on Sephadex G100, adsorption chromatography on hydroxyapatite, and preparative polyacrylamide electrophoresis. During all chromatographic procedures, the presence of immunoreactive recombinant hCG was confirmed by RIA (DRG EIA 1288) and IEF (Example 6).
• Beta-galactosamide alpha-2,6-sialyltransferase 1 Accession number NM 003032 Nucleotide sequence : ST6GAL1

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Endocrinology (AREA)
• Zoology (AREA)
• Engineering & Computer Science (AREA)
• Genetics & Genomics (AREA)
• Medicinal Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Reproductive Health (AREA)
• Wood Science & Technology (AREA)
• Gastroenterology & Hepatology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Biophysics (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Toxicology (AREA)
• General Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Biomedical Technology (AREA)
• Immunology (AREA)
• Epidemiology (AREA)
• Pregnancy & Childbirth (AREA)
• Gynecology & Obstetrics (AREA)
• Diabetes (AREA)
• Physics & Mathematics (AREA)
• Plant Pathology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)

Priority Applications (33)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=41471027

Family Applications (1)

Country Status (25)

Cited By (8)

Families Citing this family (5)

Citations (5)

Family Cites Families (26)

• 2010
  • 2010-09-27 TW TW104140348A patent/TWI604850B/zh active
  • 2010-09-27 TW TW099132570A patent/TWI532495B/zh active
  • 2010-10-04 DK DK10763000.6T patent/DK2486051T3/da active
  • 2010-10-04 KR KR1020197007226A patent/KR101987982B1/ko active Active
  • 2010-10-04 KR KR1020217003233A patent/KR20210014767A/ko not_active Ceased
  • 2010-10-04 ES ES10763000T patent/ES2798258T3/es active Active
  • 2010-10-04 KR KR1020217037028A patent/KR102489143B1/ko active Active
  • 2010-10-04 CA CA2776790A patent/CA2776790A1/en active Pending
  • 2010-10-04 HR HRP20200941TT patent/HRP20200941T1/hr unknown
  • 2010-10-04 ES ES19190372T patent/ES3036152T3/es active Active
  • 2010-10-04 EP EP10763000.6A patent/EP2486051B1/en active Active
  • 2010-10-04 JP JP2012532657A patent/JP6176924B2/ja active Active
  • 2010-10-04 KR KR1020177034392A patent/KR20170133531A/ko not_active Withdrawn
  • 2010-10-04 WO PCT/GB2010/001854 patent/WO2011042688A1/en not_active Ceased
  • 2010-10-04 US US13/500,274 patent/US8975226B2/en active Active
  • 2010-10-04 IN IN2073DEN2012 patent/IN2012DN02073A/en unknown
  • 2010-10-04 RU RU2016118236A patent/RU2724528C2/ru active
  • 2010-10-04 KR KR1020197016021A patent/KR102213154B1/ko active Active
  • 2010-10-04 KR KR1020127008827A patent/KR101804479B1/ko active Active
  • 2010-10-04 EP EP19190372.3A patent/EP3611185B1/en active Active
  • 2010-10-04 LT LTEP10763000.6T patent/LT2486051T/lt unknown
  • 2010-10-04 KR KR1020237001308A patent/KR20230012104A/ko active Pending
  • 2010-10-04 RU RU2012112907/10A patent/RU2588650C2/ru active
  • 2010-10-04 CN CN201610832288.8A patent/CN107050434B/zh active Active
  • 2010-10-04 MX MX2012003951A patent/MX2012003951A/es active IP Right Grant
  • 2010-10-04 PL PL10763000T patent/PL2486051T3/pl unknown
  • 2010-10-04 AU AU2010304922A patent/AU2010304922B2/en active Active
  • 2010-10-04 SI SI201032015T patent/SI2486051T1/sl unknown
  • 2010-10-04 PT PT107630006T patent/PT2486051T/pt unknown
  • 2010-10-04 BR BR112012007990A patent/BR112012007990A2/pt not_active Application Discontinuation
  • 2010-10-04 HU HUE10763000A patent/HUE050793T2/hu unknown
  • 2010-10-04 RS RS20200698A patent/RS60413B1/sr unknown
  • 2010-10-05 AR ARP100103608A patent/AR079876A1/es not_active Application Discontinuation
• 2012
  • 2012-03-08 IL IL218548A patent/IL218548A/en active IP Right Grant
• 2014
  • 2014-05-21 US US14/283,904 patent/US9676835B2/en active Active
• 2015
  • 2015-11-09 JP JP2015219480A patent/JP6310440B2/ja active Active
• 2017
  • 2017-02-23 IL IL250733A patent/IL250733B/en active IP Right Grant
  • 2017-05-03 US US15/586,010 patent/US10526390B2/en active Active
  • 2017-10-24 JP JP2017205012A patent/JP6580104B2/ja active Active
• 2019
  • 2019-06-20 IL IL267556A patent/IL267556A/en unknown
  • 2019-08-27 JP JP2019154226A patent/JP7292153B2/ja active Active
  • 2019-12-10 US US16/709,810 patent/US11292824B2/en active Active
• 2020
  • 2020-02-17 JO JOP/2020/0039A patent/JOP20200039A1/ar unknown
• 2021
  • 2021-07-12 JP JP2021114833A patent/JP7196244B2/ja active Active
• 2022
  • 2022-03-30 US US17/709,296 patent/US12234272B2/en active Active
  • 2022-05-27 AR ARP220101408A patent/AR125991A2/es not_active Application Discontinuation
• 2023
  • 2023-02-22 JP JP2023025781A patent/JP2023075144A/ja active Pending

Patent Citations (5)

Non-Patent Citations (18)

Also Published As

Similar Documents

Legal Events